MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria:

• Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al, 2014).

• Measurable disease based on IMWG criteria as defined by at least 1 of the following:

• Serum M-protein ≥0.5 g/dL.

• Urinary M-protein excretion ≥200 mg/24 hours.

• Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serumimmunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).

• Prior anti-multiple myeloma therapy including treatment with lenalidomide and aproteasome inhibitor.

• ECOG performance status ≤2.

• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

• Not pregnant and willing to use contraception.

Exclusion Criteria:

• Smoldering multiple myeloma.

• Plasma cell leukemia.

• Amyloidosis.

• POEMS Syndrome.

• Stem cell transplant within 12 weeks prior to enrolment, or active graft versus hostdisease.

• Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, orviral infection.

• Any other active malignancy within 3 years prior to enrolment, except for adequatelytreated basal cell or squamous cell skin cancer, or carcinoma in situ.

• Previous treatment with a BCMA-directed therapy.

• Anti-CD38-directed therapy within 6 months preceding the first dose of treatment inthis study.

• Live attenuated vaccine within 4 weeks of the first dose of study intervention.

• Administration with an investigational product (e.g. drug or vaccine) concurrentwith study intervention or within 30 days preceding the first dose of studyintervention used in this study.